Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
JAMA, 312 (4), 380
Tirzepatide, the only FDA-approved dual GIP/GLP-1 receptor agonist, is a peptide with potent and imbalanced co-agonism at both GIPR and GLP-1R
Nature 304:368371 Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Light Sci
and Smeraldi, E
US$ 25.27
US$ 28.53
US$ 29.82
US$ 20.58
